Drug Trial Radar · NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Jan 22, 2019
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally. People with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients. Pegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or "standard of care") may reduce their homocysteine levels. This study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study. Group 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.
Conditions
- Homocystinuria
Interventions
PegtibatinaseDrug
Pegtibatinase sterile solution for subcutaneous injection
PlaceboDrug
Normal saline for subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEsTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
- Anti-pegtibatinase antibodiesTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
- Anti-PEG antibodiesTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
- Incidence of hypermethioninemia (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)
- Incidence of hypomethioninemia (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)
- The proportion of participants requiring dietary protein rescue (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Travere Investigational Site
Aurora, Colorado · Completed
Travere Investigational Site
Miami, Florida · Completed
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Not yet recruiting
Travere Investigational Site
Indianapolis, Indiana · Completed
Travere Investigational Site
Portland, Maine · Completed
Travere Investigational Site
Boston, Massachusetts · Completed
The Mount Sinai Hospital
New York, New York · Not yet recruiting
Travere Investigational Site
New York, New York · Completed
Science 37 - Virtual Site
Morrisville, North Carolina · Recruiting
Travere Investigational Site
Philadelphia, Pennsylvania · Completed
Hospital Necker-Enfants Malades, Neurologie Pediatrique
Paris, France · Not yet recruiting
Sidra Medicine
Doha, Qatar · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.